Skip to content
DraconiticResearch
Search Sources API
226,742 studies31 sourcesUpdated 35 min ago
Peer-reviewedCC BY-NC-SA 4.0Journal of Clinical and Experimental Hematopathology : JCEH

A case of diffuse large B-cell lymphoma achieving complete remission with epcoritamab after pseudoprogression

6 more authors
  1. 1Department of Medical Oncology, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, Japan, Department of Pathology, Tokyo Metropolitan Cancer and Infectious Disease Center Komagome Hospital, Tokyo, Japan

Abstract

Although the use of bispecific antibodies for relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) is expanding, reports of pseudoprogression following this therapy are scarce. A 58-year-old, male patient with DLBCL achieved a complete response (CR) after fourth-line therapy with lisocabtagene maraleucel. However, 26 months post-infusion, he experienced the development of pelvic lymphadenopathy, which was histologically confirmed as a relapse. Because the disease was refractory to radiotherapy and chemotherapy, epcoritamab was administered as the seventh-line treatment. A fever developing after the second step-up dose (Cycle 1, day 12) was diagnosed as grade 1 cytokine release syndrome and was treated with acetaminophen. Nonetheless, the fever was still present on day 14, when abdominal pain requiring opioid administration also developed. Computed tomography (CT) revealed enlargement of the pelvic lesions and increased ascites. Cytology of the ascites revealed no lymphoma cells and showed a predominantly inflammatory cell composition, while lactate dehydrogenase levels decreased, supporting the diagnosis of pseudoprogression. The treatment was continued and his symptoms gradually improved. After three cycles, positron emission tomography-CT confirmed the complete metabolic response (CMR), which was maintained through nine cycles. The present case highlights the potential for pseudoprogression to occur during epcoritamab therapy, suggesting that continued treatment may lead to durable remission even in patients with early clinical deterioration.

Related

  1. Epcoritamab achieves durable remission after CD20 antigen escape in primary cardiac diffuse large B-cell lymphoma.
    Shuku Sato, Yuki Sakaida, Emi Sawazaki +4
    Annals of hematologyPeer-reviewedCC BY-NC-NDFull textGeneral medicineEurope PMCPMC
  2. Complete remission with single agent lorlatinib in children with ALK+ anaplastic large cell lymphoma and central nervous system involvement: a case report
    Crystal Wang, Yael Mossé, Lianna J. Marks +2
    Frontiers in OncologyPeer-reviewedCC BY 4.0OncologyFrontiersCrossref
  3. A Case of Advanced Hepatocellular Carcinoma with Macrovascular Invasion and Lung Metastases Achieving Pathological Complete Remission Following Sequential Multimodal Therapy: A Case Report.
    Xiongxiong Han, Yaoping Pang, Shulin Xu +4
    Journal of hepatocellular carcinomaPeer-reviewedCC BY-NCFull textGeneral medicineEurope PMCPMC
  4. FDA Approval Summary: Epcoritamab with Lenalidomide and Rituximab for Relapsed or Refractory Follicular Lymphoma
    Rachel Ershler, Xueping Zhou, Keng Hee Peh +12
    Clinical cancer research : an official journal of the American Association for Cancer ResearchPeer-reviewedLicence not statedFull textGeneral medicinePMC
  5. Successful Treatment with Epcoritamab for Refractory Diffuse Large B-cell Lymphoma in a Dialysis-dependent Patient
    Yuya Sasaki, Keisuke Tanaka, Hisako Nakamaki +4
    Internal MedicinePeer-reviewedCC BY-NC-NDFull textGeneral medicineJ-STAGE
BibTeX
@article{takahara2026case,
  title = {{A case of diffuse large B-cell lymphoma achieving complete remission with epcoritamab after pseudoprogression}},
  author = {Ai Takahara and Yu Yagi and Yusuke Kanemasa and Kaho Fujino and Takahito Kuga and Yusuke Masuda and Nozomi Kanai and Kumiko Fujita and Kento Ishimine and Taro Sawabe and Mano Mino and Taichi Tamura and Shohei Nakamura and Toshihiro Okuya and Shota Kusuhara and Shinichiro Matsuda and Tsunekazu Hishima and Tatsu Shimoyama},
  journal = {Journal of Clinical and Experimental Hematopathology : JCEH},
  year = {2026},
  month = aug,
  doi = {10.3960/jslrt.26023},
  url = {https://doi.org/10.3960/jslrt.26023},
  note = {CC BY-NC-SA 4.0},
}
RIS
TY  - JOUR
TI  - A case of diffuse large B-cell lymphoma achieving complete remission with epcoritamab after pseudoprogression
AU  - Ai Takahara
AU  - Yu Yagi
AU  - Yusuke Kanemasa
AU  - Kaho Fujino
AU  - Takahito Kuga
AU  - Yusuke Masuda
AU  - Nozomi Kanai
AU  - Kumiko Fujita
AU  - Kento Ishimine
AU  - Taro Sawabe
AU  - Mano Mino
AU  - Taichi Tamura
AU  - Shohei Nakamura
AU  - Toshihiro Okuya
AU  - Shota Kusuhara
AU  - Shinichiro Matsuda
AU  - Tsunekazu Hishima
AU  - Tatsu Shimoyama
PY  - 2026
DA  - 2026/08/29
JO  - Journal of Clinical and Experimental Hematopathology : JCEH
DO  - 10.3960/jslrt.26023
UR  - https://doi.org/10.3960/jslrt.26023
AB  - Although the use of bispecific antibodies for relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) is expanding, reports of pseudoprogression following this therapy are scarce. A 58-year-old, male patient with DLBCL achieved a complete response (CR) after fourth-line therapy with lisocabtagene maraleucel. However, 26 months post-infusion, he experienced the development of pelvic lymphadenopathy, which was histologically confirmed as a relapse. Because the disease was refractory to radiotherapy and chemotherapy, epcoritamab was administered as the seventh-line treatment. A fever developing after the second step-up dose (Cycle 1, day 12) was diagnosed as grade 1 cytokine release syndrome and was treated with acetaminophen. Nonetheless, the fever was still present on day 14, when abdominal pain requiring opioid administration also developed. Computed tomography (CT) revealed enlargement of the pelvic lesions and increased ascites. Cytology of the ascites revealed no lymphoma cells and showed a predominantly inflammatory cell composition, while lactate dehydrogenase levels decreased, supporting the diagnosis of pseudoprogression. The treatment was continued and his symptoms gradually improved. After three cycles, positron emission tomography-CT confirmed the complete metabolic response (CMR), which was maintained through nine cycles. The present case highlights the potential for pseudoprogression to occur during epcoritamab therapy, suggesting that continued treatment may lead to durable remission even in patients with early clinical deterioration.
SN  - 1346-4280
SN  - 1880-9952
ER  -